

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLCO15190)

Regd. Office: Plot No.2, Maltrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurbindo.com

(Rs. in Lakhs)

STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2015

PART I	Particulars	Stand alone				Consolidated			
		Three months ended		Year Ended		Three months ended		Year Ended	
		30.06.2015	31.03.2015	30.06.2014	31.03.2015	30.06.2015	31.03.2015	30.06.2014	31.03.2015
		Unaudited	Audited (refer note no.9)	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited
1	Income from operations								
	(a) Net sales/Income from operations (Net of excise duty)	216,314	202,042	193,456	801,800	326,372	314,397	289,461	1,204,323
	(b) Other operating income	5,648	1,799	1,644	7,710	5,664	1,810	1,646	7,729
	Total Income from operations (net)	221,962	203,841	195,100	809,510	332,036	316,207	291,107	1,212,052
2	Expenses								
	(a) Cost of material consumed	110,515	104,033	91,385	392,033	119,845	103,234	95,351	412,281
	(b) Purchase of stock-in-trade	9	114	548	1,576	32,348	33,657	46,299	171,227
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,231)	(10,382)	(603)	(15,909)	(1,410)	469	(3,587)	(32,948)
	(d) Employee benefits expense	19,182	18,851	14,800	66,875	36,508	37,332	30,209	130,226
	(e) Depreciation and amortisation expense	6,315	6,266	6,340	24,515	8,911	8,467	9,083	33,261
	(f) Provision for decline in the value of long-term investment	37,594	35,779	30,171	134,493	72,280	75,906	57,020	274,904
	(g) Other expenses	168,384	160,061	142,641	608,983	268,482	259,065	234,375	988,951
	Total expenses	53,578	43,780	52,459	200,527	63,554	57,142	56,732	223,101
3	Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	2,475	627	569	4,232	2,911	674	1,081	8,076
4	Other income	56,053	44,407	53,028	204,759	66,465	57,816	57,813	231,177
5	Profit/(Loss) from ordinary activities before finance costs, foreign exchange (gain)/loss and exceptional items (3+4)	1,504	1,409	1,385	5,658	2,085	2,260	1,885	8,431
6	Finance costs (refer note 5)	498	212	(647)	5,067	2,558	(119)	(142)	5,960
7	Foreign exchange (Gain)/Loss (refer note 5)	54,051	42,786	52,290	194,034	61,822	55,675	56,070	216,786
8	Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	54,051	42,786	52,290	194,034	61,822	55,675	56,070	216,786
9	Exceptional item	54,051	42,786	52,290	194,034	61,822	55,675	56,070	216,786
10	Profit/(Loss) from ordinary activities before tax (8-9)	13,449	9,085	12,950	42,400	18,653	15,340	14,643	59,660
11	Tax expense/(credit)	40,602	33,701	39,340	151,634	43,169	40,335	41,427	157,126
12	Net Profit/(Loss) for the period (10-11)	40,602	33,701	39,340	151,634	43,169	40,335	41,427	157,126
13	Minority interest	40,602	33,701	39,340	151,634	43,169	40,335	41,427	157,126
14	Net Profit/(Loss) after taxes and minority interest (12-13)	2,920	2,920	2,915	533,034	14,811	13,84	14,25	54,05
15	Paid-up Equity Share Capital (Face value Re. 1 per share)	13,91	13,91	13,50	52,01	14,81	13,84	14,25	54,05
16	Reserves excluding Revaluation Reserve	13,90	11,55	13,48	51,97	14,80	13,84	14,24	54,00
17	Earnings per share of Re.1/- each (not annualised)								
	(a) Basic								
	(a) Diluted								



PART II

SELECT INFORMATION FOR THE QUARTER ENDED 30.06.2015

Particulars	Three months ended			Year Ended 31.03.2015
	30.06.2015	31.03.2015	30.06.2014	
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of Shares	134,556,489	134,406,489	133,081,235	134,406,489
- Percentage of Shareholding	46.08	46.03	45.66	46.03
2 Promoters and promoter group Shareholding				
a) Pledged/Encumbered				
- Number of Shares	8,523,000	10,006,000	21,882,297	10,006,000
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	5.41	6.35	13.82	6.35
- Percentage of Shares (as a % of the total share capital of the company)	2.92	3.43	7.51	3.43
b) Non-encumbered				
- Number of Shares	148,902,786	147,569,786	136,493,489	147,569,786
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	94.59	93.65	86.18	93.65
- Percentage of Shares (as a % of the total share capital of the company)	51.00	50.54	46.83	50.54

Particulars	Three months ended 30.06.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	6
Disposed of during the quarter	6
Remaining unresolved at the end of the quarter	Nil




2/1

NOTES:

- 1 The above unaudited financial results as reviewed by the Audit Committee have been approved by the Board at its meeting held on August 12, 2015. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- 2 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and a Joint Venture.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs.177,669 lakhs (Quarter ended June 30, 2014 Rs.159,782 lakhs).
- 5 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.6,424 lakhs, Rs. Nil lakhs, Rs.1,049 lakhs, for three months ended June 30, 2015, March 31, 2015, and June 30, 2014 respectively and Rs.7,536 lakhs for the year ended March 31, 2015 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 6 The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- 7 Aurobindo Pharma (Australia) Pty Limited and its subsidiary Aurobindo Pharma NZ Limited ceased to be step down subsidiaries of the Company w.e.f. 10th April, 2015.
- 8 The Company on July 22, 2015, has allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company has increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each.
- 9 The figures of quarter ended March 31, 2015 are the balancing figures between audited figures in respect of the full financial year ended March 31st and unaudited published year to date figures upto the third quarter ended December 31st. The unaudited consolidated results published year to date figures upto the third quarter ended December 31st were not subject to limited review and the unaudited standalone results were subject to limited review.
- 10 During the previous year, on December 4, 2014, Company's USA subsidiary Aurobindo Pharma USA Inc. has acquired Natrol LLC, USA. The above Consolidated results for the quarter ended June 30, 2015 and for the quarter ended and year ended March 31, 2015 includes financial results of operations of Natrol LLC, USA from December 4, 2014. The corresponding figures of the quarter ended June 30, 2014 are not comparable.
- 11 The Board has approved an interim dividend @50% i.e. Re.0.50 (Paise fifty only) per equity share of Re.1/- (Rupee One only) for the year 2015-16.
- 12 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board



N. Gowindarajan
Managing Director



Place: Hyderabad

Date: August 12, 2015

www.aurobindo.com



Limited Review Report**Review Report to
The Board of Directors
Aurobindo Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Aurobindo Pharma Limited ('the Company') for the quarter ended June 30, 2015 (the "Statement"), except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S.R. BATLIBOI & ASSOCIATES LLP**ICAI Firm registration number: 101049W**

Chartered Accountants

per **Vikas Kumar Pansari**

Partner

Membership No.: 093649



Place : Hyderabad

Date : August 12, 2015



NEWS RELEASE

12th August 2015, Hyderabad, India

Q1 FY 2015-16 Unaudited Financials

	Q1 FY15-16 ₹ Crores	Q1 FY14-15 ₹ Crores	Y-o-Y Variance	Q4 FY14-15 ₹ Crores	Q-o-Q Variance
Consolidated Net Operating Income	3320.4	2911.1	+14.1%	3162.1	+5.0%
Operating Profit (EBIDTA) before Fx	724.7	658.2	+10.1%	656.1	+10.5%
PBT before Fx (Profit)	643.8	559.3	+15.1%	555.6	+15.9%
PAT (after minority interest)	432.4	415.4	+4.1%	403.8	+7.1%

Key Consolidated Financial Highlights for 1Q FY2015-16 (Unaudited) on Y-o-Y basis:

- Total Operating Income up by 14.1% to ₹3320.4 Crores (₹2911.1 Crores)
- Operating Profit (EBIDTA) before Fx at 21.8% (22.6%)
- Operating Profit (EBIDTA) before Fx up 10.1% to ₹724.7 Crores (₹658.2 Crores)
- PBT before Fx up by 15.1% to ₹643.8 Crores (₹559.3 Crores)
- PAT after minority interest ₹432.4 Crores (₹415.4 Crores)
- Basic & diluted EPS is ₹14.81 (₹14.25) and ₹14.80 (₹14.24)
- Formulation Sales up by 15.9% to ₹2637.1 Crores (₹2275.0 Crores)
- API Sales up by 7.9% to ₹723.0 Crores (₹670.3 Crores)
- Formulations Sales constitute 78.5% (77.2%) and API 21.5% (22.8%) of gross sales
- Interim Dividend @ 50% i.e., ₹0.50 per equity share of ₹1/- has been approved by the Board for the year 2015-16

Commenting on the Company's performance, **Mr. N. Govindarajan**, Managing Director of the company said: "We are pleased to initiate the year with broad based growth across most business verticals. We continue on our efforts towards higher degree of differentiation including specialty generics and active pharmaceutical"

Segmental Breakup of Sales (Consolidated):

(₹ in Crores)

Particulars	Q1 FY15-16	Q1 FY14-15	Y-o-Y Variance	Q4 FY14-15	Q-o-Q Variance
USA	1429.5	1115.7	+28.1%	1340.5	+6.6%
Europe	741.7	798.2	(7.1%)	769.1	(3.6%)
Row	170.6	136.9	+24.6%	140.8	+21.2%
ARV	295.3	224.2	+31.7%	267.0	+10.6%
Formulations	2637.1	2275.0	+15.9%	2517.4	+4.8%
SSPs	216.5	238.5	(9.2%)	204.8	+5.7%
Cephs	261.4	212.0	+23.3%	236.0	+10.8%
Non-Belatactum	245.1	219.8	+11.5%	235.7	+4.0%
Active Ingredients	723.0	670.3	+7.9%	676.5	+6.9%
Dossier Income	-	1.8		3.5	



Domestic and Export breakup of Gross Sales (Stand Alone):

Particulars	(₹ in Crores)				
	Q1 FY15-16	Q1 FY14-15	Y-o-Y Variance	Q4 FY14-15	Q-o-Q Variance
Domestic	481.9	387.8	+24.3%	448.3	+7.5%
Export	1776.7	1597.8	+11.2%	1624.9	+9.3%
Total Sales	2258.6	1985.6	+13.7%	2073.2	+8.9%

Global Regulatory filings :

Filings	Q1 FY15-16	Cumulative Filings as on 30 th June 2015
ANDAs (including filings made from Aurobindo USA)	3	379
DMFs (including filings made from AuroNext and AuroPeptides)	4	196
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe, South Africa and Canada)	53	2237
API DMF/COS filings in other key regulated markets	27	2423
Patents	9	603

Following approvals in USA (201 cumulative approvals including 27 tentative by USFDA) and Canada (72 cumulative approvals including 4 tentative by Health Canada) were received during the quarter ended 30th June 2015:

USA

1. Sildenafil Injection (Gx- Revatio®) 10mg/12.5mL (0.8mg/mL) - Single-use Vials - Palmonary Hypertension- Final
2. Atracurium Besylate Injection USP, [Multiple Dose Vial] 100mg/10mL (10mg/mL) – Anesthetic agent - Final
3. Atracurium Besylate Injection USP, [Single Dose Vial] 50mg/5mL (10mg/mL) – Anesthetic agent - Final
4. Cefixime for Oral Suspension USP (Gx-Suprax®) 100mg/5mL and 200mg/5mL – Antibiotic – Final
5. Metronidazole Tablets USP (Gx-Flagyl®) 250mg and 500mg - Anti-infective – Final
6. Extended Phenytoin Sodium Capsules USP (Gx-Dilantin®)100mg – CNS – Final
7. Azithromycin for Injection USP (Gx-Zithromax®) 500mg/vial - Anti-infective – Final
8. Entacapone Tablets USP (Gx-Comtan®) 200mg - Parkinson's disease - Final

Canada

1. Rizatriptan Tablets 10mg – Treatment of migraine – Final
2. Rizatriptan Benzoate Orally Dispersible Tablets 5mg & 10mg – Treatment of migraine – Final
3. Rosuvastatin Calcium Tablets 5mg, 10mg, 20mg & 40mg – CVS – Final
4. Risedronate Sodium Tablets 150mg – Osteoporosis - Final

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, Japan PMDA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 150 countries.

For further information, please contact:

Investor Relations
Aurobindo Pharma Limited
Corporate Office: WaterMark Building, Level-1
Plot No.11, Survey No. 9
Kondapur, Hitech City, Hyderabad

Phone: 040-66725000 / 66725401
Email: ir@aurobindo.com
Website : www.aurobindo.com

Reg Office: Plot No. 2, Maitrivihar
Ameerpet, Hyderabad



(CIN - L24239TG1988PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370 ; Fax: +91 40 23747340 ; Email: info@aurobindo.com

(Rs. In lakhs)

PART I								
STATEMENT OF STAND ALONE/CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER ENDED 30.06.2015								
Particulars	Stand alone				Consolidated			
	Three months ended			Year Ended	Three months ended			Year Ended
	30.06.2015	31.03.2015	30.06.2014	31.03.2015	30.06.2015	31.03.2015	30.06.2014	31.03.2015
	Unaudited	Audited (refer note no.9)	Unaudited	Audited	Unaudited	Audited (refer note no.9)	Unaudited	Audited
1 Income from operations								
(a) Net sales/income from operations (Net of excise duty)	216,314	202,042	193,456	801,800	326,372	314,397	289,461	1,204,323
(b) Other operating income	5,648	1,799	1,644	7,710	5,664	1,810	1,646	7,729
Total income from operations (net)	221,962	203,841	195,100	809,510	332,036	316,207	291,107	1,212,052
2 Expenses								
(a) Cost of material consumed	110,515	104,033	91,385	392,033	119,845	103,234	95,351	412,281
(b) Purchase of stock-in-trade	9	114	548	1,576	32,348	33,657	46,299	171,227
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(5,231)	(10,382)	(603)	(15,909)	(1,410)	469	(3,587)	(32,948)
(d) Employee benefits expense	19,182	18,851	14,800	66,875	36,608	37,332	30,209	130,226
(e) Depreciation and amortisation expense	6,315	6,266	6,340	24,515	8,911	8,467	9,083	33,261
(f) Provision for decline in the value of long-term investment	-	5,400	-	5,400	-	-	-	-
(g) Other expenses	37,594	35,779	30,171	134,493	72,280	75,906	57,020	274,904
Total expenses	168,384	160,061	142,641	608,983	268,482	259,065	234,375	988,951
3 Profit/(Loss) from operations before other income, finance costs, foreign exchange (gain)/loss and exceptional items (1-2)	53,578	43,780	52,459	200,527	63,554	57,142	56,732	223,101
4 Other Income	2,475	627	569	4,232	2,911	674	1,081	8,076
5 Profit/(Loss) from ordinary activities before finance costs , foreign exchange (gain)/ loss and exceptional items (3+4)	56,053	44,407	53,028	204,759	66,465	57,816	57,813	231,177
6 Finance costs (refer note 5)	1,504	1,409	1,385	5,658	2,085	2,260	1,885	8,431
7 Foreign exchange (Gain)/Loss (refer note 5)	498	212	(647)	5,067	2,558	(119)	(142)	5,960
8 Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6-7)	54,051	42,786	52,290	194,034	61,822	55,675	56,070	216,786
9 Exceptional item	-	-	-	-	-	-	-	-
10 Profit /(Loss) from ordinary activities before tax (8-9)	54,051	42,786	52,290	194,034	61,822	55,675	56,070	216,786
11 Tax expense/(credit)	13,449	9,085	12,950	42,400	18,653	15,340	14,643	59,660
12 Net Profit /(Loss) for the period (10-11)	40,602	33,701	39,340	151,634	43,169	40,335	41,427	157,126
13 Minority Interest	-	-	-	-	(75)	(45)	(116)	(451)
14 Net Profit/(Loss) after taxes and minority interest (12-13)	40,602	33,701	39,340	151,634	43,244	40,380	41,543	157,577
15 Paid-up Equity Share Capital (Face value Re. 1 per share)	2,920	2,920	2,915	2,920				
16 Reserves excluding Revaluation Reserve				533,034				
17 Earnings per share of Re.1/- each (not annualised)								
(a) Basic	13.91	11.55	13.50	52.01	14.81	13.84	14.25	54.05
(a) Diluted	13.90	11.55	13.48	51.97	14.80	13.84	14.24	54.00

PART II				
SELECT INFORMATION FOR THE QUARTER ENDED 30.06.2015				
Particulars	Three months ended			Year Ended
	30.06.2015	31.03.2015	30.06.2014	31.03.2015
A PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of Shares	134,556,489	134,406,489	133,081,235	134,406,489
- Percentage of Shareholding	46.08	46.03	45.66	46.03
2 Promoters and promoter group Shareholding				
a) Pledged/Encumbered				
- Number of Shares	8,523,000	10,006,000	21,882,297	10,006,000
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	5.41	6.35	13.82	6.35
- Percentage of Shares (as a % of the total share capital of the company)	2.92	3.43	7.51	3.43
b) Non-encumbered				
- Number of Shares	148,902,786	147,569,786	136,493,489	147,569,786
- Percentage of Shares (as a % of the total shareholding of promoter & promoter group)	94.59	93.65	86.18	93.65
- Percentage of Shares (as a % of the total share capital of the company)	51.00	50.54	46.83	50.54

Particulars	Three months ended 30.06.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	Nil
Received during the quarter	6
Disposed of during the quarter	6
Remaining unresolved at the end of the quarter	Nil



NOTES:

- 1 The above unaudited financial results as reviewed by the Audit Committee have been approved by the Board at its meeting held on August 12, 2015. A Limited Review of the above stand alone financial results has been carried out by the Statutory Auditors.
- 2 The consolidated financial results have been prepared in accordance with AS - 21 on 'Consolidated Financial Statement' and AS-27 'Financial Reporting of Interests in Joint Ventures' and includes financial results of all Subsidiaries and a Joint Venture.
- 3 The Company's operations fall within a single primary business segment viz. 'Pharmaceutical Products'.
- 4 Sales of standalone for the current quarter include exports Rs.177,669 lakhs (Quarter ended June 30, 2014 Rs.159,782 lakhs).
- 5 Foreign exchange (gain)/loss for stand alone and consolidated includes exchange difference of Rs.6,424 lakhs, Rs.Nil lakhs, Rs.1,049 lakhs, for three months ended June 30, 2015, March 31, 2015, and June 30, 2014 respectively and Rs.7,556 lakhs for the year ended March 31, 2015 arising from foreign currency borrowings to the extent that they are regarded as an adjustment to finance cost as per para 4(e) of "AS 16" on Borrowing costs.
- 6 The Board of Directors at their meeting held on September 12, 2013 decided to transfer its injectable unit of the Company on a going concern basis comprising assets and liabilities pertaining to the said unit to its wholly owned subsidiary Curepro Parenterals Limited w.e.f. April 1, 2014. The same is subject to requisite consent, approval or permission of the statutory or regulatory authorities. Pending such approvals, no effect of this scheme has been given in the above results.
- 7 Aurobindo Pharma (Australia) Pty Limited and its subsidiary Aurobindo Pharma NZ Limited ceased to be step down subsidiaries of the Company w.e.f. 10th April, 2015.
- 8 The Company on July 22, 2015, has allotted 291,982,275 equity shares of Re.1/- each to the shareholders of the Company as Bonus shares in the ratio of 1:1. Consequent to the aforesaid allotment, the paid up equity share capital of the Company has increased from 291,982,275 Equity Shares of Re.1/- each to 583,964,550 Equity Shares of Re.1/- each.
- 9 The figures of quarter ended March 31, 2015 are the balancing figures between audited figures in respect of the full financial year ended March 31st and unaudited published year to date figures upto the third quarter ended December 31st. The unaudited consolidated results published year to date figures upto the third quarter ended December 31st were not subject to limited review and the unaudited standalone results were subject to limited review.
- 10 During the previous year, on December 4, 2014, Company's USA subsidiary Aurobindo Pharma USA Inc. has acquired Natrol LLC, USA. The above Consolidated results for the quarter ended June 30, 2015 and for the quarter ended and year ended March 31, 2015 includes financial results of operations of Natrol LLC, USA from December 4, 2014. The corresponding figures of the quarter ended June 30, 2014 are not comparable.
- 11 The Board has approved an interim dividend @50% i.e. Re.0.50 (Paise fifty only) per equity share of Re1/-(Rupee One only) for the year 2015-16.
- 12 Previous period figures have been regrouped/rearranged wherever considered necessary to conform to the current period presentation.

By Order of the Board

Place: Hyderabad
Date :August 12, 2015

www.aurobindo.com

N.Govindarajan
Managing Director